Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 3/20 | 0.50 |
| ▸ | ITGAV | P06756 | 3/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2291392 | 0.92 | KMT2A (0.51) | ITGB3ITGAVNR1I2KMT2AHPGD | |
| SCHEMBL5292268 | 0.87 | LMNA (0.49) | ITGB3ITGAVADRA2BKMT2AHPGD | |
| SCHEMBL2297135 | 0.86 | KMT2A (0.46) | NR1I2KMT2AHPGDALDH1A1NPC1 | |
| SCHEMBL2299666 | 0.85 | KMT2A (0.48) | NR1I2KMT2AKDM4ENPC1RAB9A | |
| SCHEMBL2300667 | 0.85 | RAB9A (0.51) | KMT2AKDM4EUSP2ALDH1A1POLB | |
| SCHEMBL5305129 | 0.85 | NPC1 (0.49) | NR1I2KMT2AKDM4ENPC1RAB9A | |
| SCHEMBL2299814 | 0.85 | LMNA (0.45) | NR1I2KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL5295744 | 0.84 | BCHE (0.46) | NR1I2KMT2AKDM4ENPC1RAB9A | |
| SCHEMBL2294482 | 0.84 | NAMPT (0.48) | ITGB3ITGAVNR1I2KMT2AKDM4E | |
| SCHEMBL2291248 | 0.83 | USP2 (0.51) | NR1I2KMT2AHPGDUSP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003806-B2 | Integrin antagonists useful as anticancer agents | OSI Pharmaceuticals, LLC (US) | 2011-08-23 | — | — | US | claimed |
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ALCATEL LUCENT (FR) | 2006-06-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ITGB5, ITGA5, ITGB1 | ITGB3 10/4885ITGAV 13/4885ADRA2B 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.